Posts tagged Tongue v. Sanofi.
On March 4, 2016, the United States Court of Appeals for the Second Circuit affirmed the District Court for the Southern District of New York in Tongue v. Sanofi, No. 15-588-CV, 2016 WL 851797 (2d Cir. Mar. 4, 2016), holding that the District Court properly dismissed the Investor Plaintiffs/Appellants' Complaint. The Plaintiffs alleged that the Defendants, a pharmaceutical company, its predecessor, and three executives, violated § § 10(b), 18, and 20(a) of the Securities Exchange Act of 1934, § § 11 and 12 of the Securities Act of 1933, and state law by making misleading statements ...
Posted in: Securities Act of 1933
Tags: Biologics License Application, FDA, Genzyme Corporation, Lemtrada, multiple sclerosis Lemtrada, Securities Act of 1933, Securities Exchange Act of 1934, Supplemental Biologics Application, Tongue v. Sanofi